ALT vs. IMUX

In the year-to-date period, ALT achieves a -26.49% return, which is significantly higher than IMUX's -30.00% return. Over the past 10 years, ALT has outperformed IMUX with an annualized return of -37.00%, while IMUX has yielded a comparatively lower -51.19% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Altimmune, Inc. (ALT) and Immunic, Inc. (IMUX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current ALT Sharpe Ratio is -0.36, which is higher than the IMUX Sharpe Ratio of -0.55. The chart below compares the historical Sharpe Ratios of ALT and IMUX, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither ALT nor IMUX has paid dividends to shareholders.

The maximum ALT drawdown since its inception was -99.94%, roughly equal to the maximum IMUX drawdown of -99.95%. Use the drawdown chart below to compare losses from any high point for ALT and IMUX.

The current volatility for Altimmune, Inc. (ALT) is 23.45%, while Immunic, Inc. (IMUX) has a volatility of 31.61%. This indicates that ALT experiences smaller price fluctuations and is considered to be less risky than IMUX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Altimmune, Inc. and Immunic, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.